<li>acebutolol<p>acebutolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of acebutolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>aceclofenac<p>aceclofenac and celecoxib both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aceclofenac and celecoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>acemetacin<p>acemetacin and celecoxib both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>acemetacin and celecoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>agrimony<p>celecoxib and agrimony both increase  anticoagulation. Use Caution/Monitor.</p></li><li>albuterol<p>celecoxib increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>alfalfa<p>celecoxib and alfalfa both increase  anticoagulation. Use Caution/Monitor.</p></li><li>alfuzosin<p>celecoxib decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>alteplase<p>celecoxib and alteplase both increase  anticoagulation. Use Caution/Monitor. Potential for increased risk of bleeding, caution is advised.</p></li><li>aluminum hydroxide<p>aluminum hydroxide decreases levels of celecoxib by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>american ginseng<p>celecoxib and american ginseng both increase  anticoagulation. Use Caution/Monitor.</p></li><li>amiloride<p>amiloride and celecoxib both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>antithrombin alfa<p>antithrombin alfa and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>antithrombin iii<p>antithrombin iii and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>arformoterol<p>celecoxib increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>argatroban<p>argatroban and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>asenapine<p>celecoxib decreases effects of asenapine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>aspirin<p>aspirin and celecoxib both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and celecoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>aspirin rectal<p>aspirin rectal and celecoxib both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin rectal and celecoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate and celecoxib both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin/citric acid/sodium bicarbonate and celecoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>atenolol<p>atenolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of atenolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>atomoxetine<p>celecoxib will increase the level or effect of atomoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>azficel-t<p>azficel-t, celecoxib. Other (see comment). Use Caution/Monitor. 
Comment: Patients taking NSAIDS may experience increased bruising or bleeding at biopsy and/or injection sites. Concomitant use of NSAIDs is not recommended.</p></li><li>azilsartan<p>celecoxib, azilsartan.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.<span><br><br></span>celecoxib decreases effects of azilsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.</p></li><li>bambuterol<p>celecoxib increases and bambuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>bemiparin<p>bemiparin and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>benazepril<p>benazepril, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>bendroflumethiazide<p>celecoxib increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>betaxolol<p>betaxolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of betaxolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>bisoprolol<p>bisoprolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of bisoprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>bivalirudin<p>bivalirudin and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>budesonide<p>celecoxib, budesonide.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>bumetanide<p>celecoxib increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of bumetanide by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>calcium carbonate<p>calcium carbonate decreases levels of celecoxib by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>candesartan<p>candesartan and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of candesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>candesartan, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>captopril<p>captopril, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>carbenoxolone<p>celecoxib increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>carvedilol<p>celecoxib will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>carvedilol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>celiprolol<p>celiprolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of celiprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>chlorothiazide<p>celecoxib increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>chlorpropamide<p>celecoxib increases effects of chlorpropamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>chlorthalidone<p>celecoxib increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>choline magnesium trisalicylate<p>celecoxib and choline magnesium trisalicylate both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and choline magnesium trisalicylate both increase  serum potassium. Use Caution/Monitor.</p></li><li>cinnamon<p>celecoxib and cinnamon both increase  anticoagulation. Use Caution/Monitor.</p></li><li>ciprofloxacin<p>ciprofloxacin, celecoxib. Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Mechanism: unknown. Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones.</p></li><li>citalopram<p>citalopram, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>clobetasone<p>celecoxib, clobetasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>clomipramine<p>celecoxib will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>clomipramine, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.</p></li><li>clopidogrel<p>clopidogrel, celecoxib.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Clopidogrel and NSAIDs both inhibit platelet aggregation.</p></li><li>codeine<p>celecoxib decreases effects of codeine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Prevents conversion of codeine to its active metabolite morphine.</p></li><li>cordyceps<p>celecoxib and cordyceps both increase  anticoagulation. Use Caution/Monitor.</p></li><li>cortisone<p>celecoxib, cortisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>cyclopenthiazide<p>celecoxib increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>cyclosporine<p>celecoxib, cyclosporine.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.</p></li><li>dabigatran<p>dabigatran and celecoxib both increase  anticoagulation. Use Caution/Monitor. Caution is advised, both drugs have the potential to cause bleeding. Concomitant use may increase risk of bleeding.</p></li><li>dalteparin<p>dalteparin and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>defibrotide<p>defibrotide increases effects of celecoxib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Defibrotide may enhance effects of platelet inhibitors.</p></li><li>deflazacort<p>celecoxib, deflazacort.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>desipramine<p>celecoxib will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>dexamethasone<p>celecoxib, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>dichlorphenamide<p>dichlorphenamide and celecoxib both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>celecoxib and diclofenac both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and diclofenac both increase  serum potassium. Use Caution/Monitor.</p></li><li>diflunisal<p>celecoxib and diflunisal both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and diflunisal both increase  serum potassium. Use Caution/Monitor.</p></li><li>digoxin<p>celecoxib and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>dobutamine<p>celecoxib increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dong quai<p>celecoxib and dong quai both increase  anticoagulation. Use Caution/Monitor.</p></li><li>dopexamine<p>celecoxib increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>doxazosin<p>celecoxib decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>doxepin<p>celecoxib will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>drospirenone<p>drospirenone and celecoxib both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>duloxetine<p>celecoxib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>duloxetine, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>edoxaban<p>edoxaban, celecoxib.
Either increases toxicity of the other by anticoagulation. Modify Therapy/Monitor Closely. Both drugs have the potential to cause bleeding, monitor closely. Promptly evaluate any signs or symptoms of blood loss.</p></li><li>efavirenz<p>efavirenz will increase the level or effect of celecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.</p></li><li>eltrombopag<p>eltrombopag increases levels of celecoxib by decreasing metabolism. Use Caution/Monitor. UGT inhibition; significance of interaction unclear.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df decreases levels of celecoxib by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Elvitegravir is a moderate CYP2C9 inducer.<span><br><br></span>elvitegravir/cobicistat/emtricitabine/tenofovir df, celecoxib.
Either increases toxicity of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of emtricitabine and tenofovir with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered.</p></li><li>emtricitabine<p>emtricitabine, celecoxib.
Either increases levels of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of emtricitabine with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered.</p></li><li>enalapril<p>enalapril, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment:  May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>enoxaparin<p>enoxaparin and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>ephedrine<p>celecoxib increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ephedrine (pulmonary)<p>celecoxib increases and ephedrine (pulmonary) decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>epinephrine<p>celecoxib increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>epinephrine racemic<p>celecoxib increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>epoprostenol<p>celecoxib and epoprostenol both increase  anticoagulation. Use Caution/Monitor.</p></li><li>eprosartan<p>eprosartan and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of eprosartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>eprosartan, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>escitalopram<p>escitalopram, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>esmolol<p>esmolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of esmolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>ethacrynic acid<p>celecoxib increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>etodolac<p>celecoxib and etodolac both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and etodolac both increase  serum potassium. Use Caution/Monitor.</p></li><li>etoricoxib<p>celecoxib and etoricoxib both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and etoricoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>fenbufen<p>celecoxib and fenbufen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and fenbufen both increase  serum potassium. Use Caution/Monitor.</p></li><li>fennel<p>celecoxib and fennel both increase  anticoagulation. Use Caution/Monitor.</p></li><li>fenoprofen<p>celecoxib and fenoprofen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and fenoprofen both increase  serum potassium. Use Caution/Monitor.</p></li><li>feverfew<p>celecoxib and feverfew both increase  anticoagulation. Use Caution/Monitor.</p></li><li>flecainide<p>celecoxib will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>flucloxacillin<p>flucloxacillin, celecoxib.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>flucloxacillin, celecoxib.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>fludrocortisone<p>celecoxib, fludrocortisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>fluoxetine<p>fluoxetine will increase the level or effect of celecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>celecoxib will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>fluoxetine, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>flurbiprofen<p>celecoxib and flurbiprofen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and flurbiprofen both increase  serum potassium. Use Caution/Monitor.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of celecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>fluvoxamine, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fondaparinux<p>fondaparinux and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>formoterol<p>celecoxib increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>forskolin<p>celecoxib and forskolin both increase  anticoagulation. Use Caution/Monitor.</p></li><li>fosinopril<p>fosinopril, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment:  May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>furosemide<p>celecoxib increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>garlic<p>celecoxib and garlic both increase  anticoagulation. Use Caution/Monitor.</p></li><li>gemifloxacin<p>gemifloxacin, celecoxib. Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones.</p></li><li>gentamicin<p>celecoxib increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ginger<p>celecoxib and ginger both increase  anticoagulation. Use Caution/Monitor.</p></li><li>ginkgo biloba<p>celecoxib and ginkgo biloba both increase  anticoagulation. Use Caution/Monitor.</p></li><li>glimepiride<p>celecoxib increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>glipizide<p>celecoxib increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>gliquidone<p>celecoxib increases effects of gliquidone by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>glyburide<p>celecoxib increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>haloperidol<p>celecoxib will increase the level or effect of haloperidol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>heparin<p>heparin and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>horse chestnut seed<p>celecoxib and horse chestnut seed both increase  anticoagulation. Use Caution/Monitor.</p></li><li>hydralazine<p>celecoxib decreases effects of hydralazine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>hydrochlorothiazide<p>celecoxib increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>hydrocodone<p>celecoxib will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>hydrocortisone<p>celecoxib, hydrocortisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>hydromorphone<p>celecoxib will increase the level or effect of hydromorphone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>ibuprofen<p>celecoxib and ibuprofen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and ibuprofen both increase  serum potassium. Use Caution/Monitor.</p></li><li>iloperidone<p>celecoxib will increase the level or effect of iloperidone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>imatinib<p>imatinib will increase the level or effect of celecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.<span><br><br></span>imatinib, celecoxib.
Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Imatinib may cause thrombocytopenia; bleeding risk increased when imatinib is   coadministered with anticoagulants, NSAIDs, platelet inhibitors, and thrombolytic agents.</p></li><li>imipramine<p>celecoxib will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>indapamide<p>celecoxib increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>indomethacin<p>celecoxib and indomethacin both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and indomethacin both increase  serum potassium. Use Caution/Monitor.</p></li><li>irbesartan<p>irbesartan and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of irbesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>irbesartan, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment:  May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>isoproterenol<p>celecoxib increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ketoprofen<p>celecoxib and ketoprofen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and ketoprofen both increase  serum potassium. Use Caution/Monitor.</p></li><li>ketorolac<p>celecoxib and ketorolac both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and ketorolac both increase  serum potassium. Use Caution/Monitor.</p></li><li>ketorolac intranasal<p>celecoxib and ketorolac intranasal both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and ketorolac intranasal both increase  serum potassium. Use Caution/Monitor.</p></li><li>labetalol<p>labetalol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>lepirudin<p>lepirudin and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>levalbuterol<p>celecoxib increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>levofloxacin<p>levofloxacin, celecoxib. Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Risk of CNS stimulation/seizure.  Mechanism: Displacement of GABA from receptors in brain.</p></li><li>levomilnacipran<p>levomilnacipran, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. SNRIs may further impair platelet activity in patients taking antiplatelet or anticoagulant drugs.</p></li><li>lisinopril<p>lisinopril, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>lithium<p>celecoxib increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.</p></li><li>lofepramine<p>celecoxib will increase the level or effect of lofepramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lornoxicam<p>celecoxib and lornoxicam both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and lornoxicam both increase  serum potassium. Use Caution/Monitor.</p></li><li>losartan<p>losartan and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, celecoxib. affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C9 substrates. .</p></li><li>meclofenamate<p>celecoxib and meclofenamate both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and meclofenamate both increase  serum potassium. Use Caution/Monitor.</p></li><li>mefenamic acid<p>celecoxib and mefenamic acid both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and mefenamic acid both increase  serum potassium. Use Caution/Monitor.</p></li><li>meloxicam<p>celecoxib and meloxicam both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and meloxicam both increase  serum potassium. Use Caution/Monitor.</p></li><li>mesalamine<p>mesalamine, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive nephrotoxicity.</p></li><li>metaproterenol<p>celecoxib increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>methamphetamine<p>celecoxib will increase the level or effect of methamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>methyclothiazide<p>celecoxib increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>methylprednisolone<p>celecoxib, methylprednisolone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>metolazone<p>celecoxib increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>metoprolol<p>celecoxib will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>metoprolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of metoprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>mexiletine<p>celecoxib will increase the level or effect of mexiletine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mibefradil<p>celecoxib will increase the level or effect of mibefradil by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>milnacipran<p>milnacipran, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>mipomersen<p>mipomersen, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>mistletoe<p>celecoxib increases and mistletoe decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>moexipril<p>moexipril, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>morphine<p>celecoxib will increase the level or effect of morphine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>moxifloxacin<p>moxifloxacin, celecoxib. Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Increased risk of CNS stimulation and seizures with high doses of fluoroquinolones.</p></li><li>moxisylyte<p>celecoxib decreases effects of moxisylyte by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>mycophenolate<p>celecoxib will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>nabumetone<p>celecoxib and nabumetone both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and nabumetone both increase  serum potassium. Use Caution/Monitor.</p></li><li>nadolol<p>nadolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of nadolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>naproxen<p>celecoxib and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>nebivolol<p>celecoxib will increase the level or effect of nebivolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>nebivolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of nebivolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>nefazodone<p>nefazodone, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>nettle<p>celecoxib increases and nettle decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>norepinephrine<p>celecoxib increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>nortriptyline<p>celecoxib will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>olmesartan<p>olmesartan and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of olmesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>olmesartan, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>oxaprozin<p>celecoxib and oxaprozin both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and oxaprozin both increase  serum potassium. Use Caution/Monitor.</p></li><li>oxycodone<p>celecoxib will increase the level or effect of oxycodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>oxymorphone<p>celecoxib will increase the level or effect of oxymorphone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>paclitaxel<p>celecoxib will increase the level or effect of paclitaxel by  Other (see comment). Use Caution/Monitor. Paclitaxel levels/toxicity may increase when coadministered with CYP2C8 inhibitors </p></li><li>paclitaxel protein bound<p>celecoxib will increase the level or effect of paclitaxel protein bound by  Other (see comment). Use Caution/Monitor. Paclitaxel levels/toxicity may increase when coadministered with CYP2C8 inhibitors </p></li><li>panax ginseng<p>celecoxib and panax ginseng both increase  anticoagulation. Use Caution/Monitor.</p></li><li>parecoxib<p>celecoxib and parecoxib both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and parecoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>paroxetine<p>paroxetine, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>pau d'arco<p>celecoxib and pau d'arco both increase  anticoagulation. Use Caution/Monitor.</p></li><li>pegaspargase<p>pegaspargase increases effects of celecoxib by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of bleeding events.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b decreases levels of celecoxib by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. When patients are administered peginterferon alpha-2b with CYP2C9 substrates, the therapeutic effect of these drugs may be altered.</p></li><li>penbutolol<p>penbutolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of penbutolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>perindopril<p>perindopril, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>phenindione<p>phenindione and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>phenoxybenzamine<p>celecoxib decreases effects of phenoxybenzamine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>phentolamine<p>celecoxib decreases effects of phentolamine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>phytoestrogens<p>celecoxib and phytoestrogens both increase  anticoagulation. Use Caution/Monitor.</p></li><li>pindolol<p>pindolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of pindolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>pirbuterol<p>celecoxib increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>piroxicam<p>celecoxib and piroxicam both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and piroxicam both increase  serum potassium. Use Caution/Monitor.</p></li><li>pivmecillinam<p>pivmecillinam, celecoxib.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>pivmecillinam, celecoxib.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>potassium acid phosphate<p>celecoxib and potassium acid phosphate both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>potassium chloride<p>celecoxib and potassium chloride both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>potassium citrate<p>celecoxib and potassium citrate both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>pralatrexate<p>celecoxib increases levels of pralatrexate by decreasing renal clearance. Use Caution/Monitor. NSAIDs may delay pralatrexate clearance, increasing drug exposure. Adjust the pralatrexate dose as needed.</p></li><li>prazosin<p>celecoxib decreases effects of prazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>prednisolone<p>celecoxib, prednisolone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>prednisone<p>celecoxib, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>probenecid<p>celecoxib will increase the level or effect of probenecid by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>propafenone<p>celecoxib will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>propranolol<p>celecoxib will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>propranolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of propranolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>protamine<p>protamine and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>quinapril<p>quinapril, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>ramipril<p>ramipril, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>reishi<p>celecoxib and reishi both increase  anticoagulation. Use Caution/Monitor.</p></li><li>reteplase<p>celecoxib and reteplase both increase  anticoagulation. Use Caution/Monitor. Potential for increased risk of bleeding, caution is advised.</p></li><li>rivaroxaban<p>rivaroxaban, celecoxib. Other (see comment). Use Caution/Monitor. 
Comment: NSAIDs are known to increase bleeding. Bleeding risk may be increased when NSAIDs are used concomitantly with rivaroxaban. Monitor for signs/symptoms of blood loss.</p></li><li>rivastigmine<p>rivastigmine increases toxicity of celecoxib by pharmacodynamic synergism. Use Caution/Monitor. Monitor patients for symptoms of active or occult gastrointestinal bleeding.</p></li><li>sacubitril/valsartan<p>sacubitril/valsartan and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sacubitril/valsartan, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.<span><br><br></span>celecoxib decreases effects of sacubitril/valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.</p></li><li>salicylates (non-asa)<p>celecoxib and salicylates (non-asa) both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and salicylates (non-asa) both increase  serum potassium. Use Caution/Monitor.</p></li><li>salmeterol<p>celecoxib increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>salsalate<p>celecoxib and salsalate both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and salsalate both increase  serum potassium. Use Caution/Monitor.</p></li><li>sertindole<p>celecoxib will increase the level or effect of sertindole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>sertraline<p>sertraline, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>siberian ginseng<p>celecoxib and siberian ginseng both increase  anticoagulation. Use Caution/Monitor.</p></li><li>silodosin<p>celecoxib decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>sodium bicarbonate<p>sodium bicarbonate decreases levels of celecoxib by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>sodium citrate/citric acid<p>sodium citrate/citric acid decreases levels of celecoxib by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.</p></li><li>sodium picosulfate/magnesium oxide/anhydrous citric acid<p>celecoxib, sodium picosulfate/magnesium oxide/anhydrous citric acid.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May be associated with fluid and electrolyte imbalances.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate<p>celecoxib, sodium sulfate/potassium sulfate/magnesium sulfate. serum potassium. Modify Therapy/Monitor Closely.<span><br><br></span>celecoxib, sodium sulfate/potassium sulfate/magnesium sulfate. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol<p>celecoxib, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sotalol<p>sotalol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>spironolactone<p>spironolactone and celecoxib both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>succinylcholine<p>celecoxib and succinylcholine both increase  serum potassium. Use Caution/Monitor.</p></li><li>sulfasalazine<p>celecoxib and sulfasalazine both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and sulfasalazine both increase  serum potassium. Use Caution/Monitor.</p></li><li>sulindac<p>celecoxib and sulindac both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and sulindac both increase  serum potassium. Use Caution/Monitor.</p></li><li>tamoxifen<p>celecoxib decreases effects of tamoxifen by decreasing metabolism. Use Caution/Monitor. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.</p></li><li>telmisartan<p>telmisartan and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of telmisartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>telmisartan, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>temocillin<p>temocillin, celecoxib.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>temocillin, celecoxib.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>tenecteplase<p>celecoxib and tenecteplase both increase  anticoagulation. Use Caution/Monitor. Potential for increased risk of bleeding, caution is advised.</p></li><li>tenofovir df<p>tenofovir df, celecoxib.
Either increases levels of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of  tenofovir DF with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered.</p></li><li>terazosin<p>celecoxib decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>terbutaline<p>celecoxib increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ticarcillin<p>ticarcillin, celecoxib.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>ticarcillin, celecoxib.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>timolol<p>celecoxib will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>timolol and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of timolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>tinzaparin<p>tinzaparin and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>tobramycin inhaled<p>tobramycin inhaled and celecoxib both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity</p></li><li>tolazamide<p>celecoxib increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>tolbutamide<p>celecoxib increases effects of tolbutamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>tolfenamic acid<p>celecoxib and tolfenamic acid both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and tolfenamic acid both increase  serum potassium. Use Caution/Monitor.</p></li><li>tolmetin<p>celecoxib and tolmetin both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>celecoxib and tolmetin both increase  serum potassium. Use Caution/Monitor.</p></li><li>tolvaptan<p>celecoxib and tolvaptan both increase  serum potassium. Use Caution/Monitor.</p></li><li>torsemide<p>celecoxib increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>tramadol<p>celecoxib decreases effects of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Decreased conversion of tramadol to active metabolite.<span><br><br></span>celecoxib decreases effects of tramadol by decreasing metabolism. Use Caution/Monitor. Decreased conversion of tramadol to active metabolite.</p></li><li>trandolapril<p>trandolapril, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>trazodone<p>trazodone, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>triamcinolone<p>celecoxib, triamcinolone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>triamterene<p>triamterene and celecoxib both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>valsartan<p>valsartan and celecoxib both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>celecoxib decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, celecoxib.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>venlafaxine<p>venlafaxine, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>vorapaxar<p>celecoxib, vorapaxar.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur.</p></li><li>vortioxetine<p>celecoxib, vortioxetine.
Either increases effects of the other by anticoagulation. Use Caution/Monitor.</p></li><li>warfarin<p>warfarin and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>zotepine<p>celecoxib decreases effects of zotepine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li>